Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial

Relapsed Ovarian Cancer Clinical Trial

Official title:
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicenter, Open-label, Randomized, Phase 3 Trial

Status Recruiting

Clinical Trial Summary

This study aims to carry out a multi-center, randomized controlled study on patients with recurrent ovarian cancer after PARPi maintenance, to explore the clinicopathological and molecular characteristics of patients with recurrent ovarian cancer after PARPi maintenance, and to clarify whether patients with recurrent ovarian cancer after PARPi maintenance for more than 6 months are sensitive to platinum drugs, and the value of secondary tumor cell reduction in such treatment, In order to provide evidence-based medicine basis for the standardized treatment mode of recurrent ovarian cancer after PARPi maintenance treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05607329
Study type	Interventional
Source	Women's Hospital School Of Medicine Zhejiang University
Contact
Status	Recruiting
Phase	N/A
Start date	May 1, 2021
Completion date	May 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01874353` - Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy	Phase 3
Not yet recruiting	`NCT06081595` - Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment	Phase 2
Recruiting	`NCT04517357` - A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients	Phase 2
Recruiting	`NCT04887961` - Reprab Study: PLD + Trabectedin Rechallenge	Phase 2
Active, not recruiting	`NCT03534453` - Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy	Phase 3
Recruiting	`NCT05080556` - Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer	Phase 2
Terminated	`NCT04999605` - A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer	Phase 1/Phase 2
Completed	`NCT02825420` - Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
Recruiting	`NCT04713514` - OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC	Phase 2
Not yet recruiting	`NCT05479487` - Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment	Phase 2